The adjourned meeting on October 1, 2026 for Proposals 3-6 is the key catalyst — Nasdaq's conditional approval of the Initial Listing Application is required before those votes can proceed. Monitor for Nasdaq decision and subsequent director resignations signaling the change of control.
Price Chart
Executive Summary
Adial Pharmaceuticals filed this DEFA14A to report results from its 2026 Annual Meeting held September 17, 2026. Stockholders approved all twelve proposals with overwhelming support, including a 5x increase in authorized shares (from 100M to 500M), new equity incentive plans with a 3,078,147 share reserve, and a warrant exercise proposal for 552,940 shares. The meeting was partially adjourned to October 1, 2026 for four proposals pending Nasdaq conditional approval, while the two incumbent directors were re-elected but are expected to resign shortly after all proposals are approved, signaling a pending change of control.
Key Financial Metrics
Key Facts
- Stockholders approved increasing authorized common shares from 100,000,000 to 500,000,000 (5x increase).
- Stockholders approved the 2026 Equity Incentive Plan with a 3,078,147 share reserve plus annual 5% evergreen increases through 2036.
- Stockholders approved the 2026 Employee Stock Purchase Plan with a 307,815 share reserve plus annual 1% evergreen increases through 2036.
- Stockholders approved the issuance of up to 552,940 shares upon exercise of Series F warrants from the November 28, 2025 private placement.
- The meeting was adjourned for Proposals 3-6 until October 1, 2026 pending Nasdaq conditional approval of an Initial Listing Application.
- Incumbent directors Cary Claiborne and Robertson Gilliland were re-elected but are expected to resign shortly after all proposals are approved.
- Quorum was 1,278,677 shares (48.7% of 2,625,890 outstanding shares).
Financial Impact
Authorized share count increased 5x from 100M to 500M; new equity plans reserve up to 3,078,147 shares plus annual evergreen increases; 552,940 shares issuable upon warrant exercise.
Risk Factors
- Nasdaq may not grant conditional approval for the Initial Listing Application, delaying or blocking Proposals 3-6.
- Pending director resignations after all proposals are approved create uncertainty about future board composition and strategic direction.
- Massive authorized share increase (5x) and new equity plans create significant potential future dilution.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-101500 |
| Document: 0001213900-26-101500-index-headers.html | 0001213900-26-101500 |
| Document: 0001213900-26-101500-index.html | 0001213900-26-101500 |
| Document: 0001213900-26-101500.txt | 0001213900-26-101500 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $3.68 | awaiting T+60 | — | $3.81 (−3.40%) |
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.81 (+7.42%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.81 (+7.42%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.81 (−5.11%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.81 (−5.11%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.81 (−7.87%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.81 (−13.52%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.81 (−13.52%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.81 (−26.97%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.81 (−26.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers